Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,224,905

« Back to Dashboard
Patent 6,224,905 protects RISPERDAL and is included in one NDA. There have been two Paragraph IV challenges on Risperdal. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for RISPERDAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-seven countries.

Summary for Patent: 6,224,905

Title: Biconvex rapidly disintegrating dosage forms
Abstract:A method for preparing solid rapidly disintegrating dosage forms shaped as biconvex tablets having symmetrical top and bottom surfaces and dosage forms obtainable thereby.
Inventor(s): Lawrence; Janice (Gregory, MI), Posage; Gary (Rochester Hills, MI)
Assignee: Janssen Pharmaceutica N.V. (BE)
Application Number:09/194,808
Patent Claim Types:
see list of patent claims
Dosage form; Process; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 6th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
TABLET, ORALLY DISINTEGRATING;ORAL021444-001Apr 2, 2003RXNo6,224,905*PEDDec 10, 2017Y
Janssen Pharms
TABLET, ORALLY DISINTEGRATING;ORAL021444-002Apr 2, 2003RXYes6,224,905*PEDDec 10, 2017Y
Janssen Pharms
TABLET, ORALLY DISINTEGRATING;ORAL021444-003Apr 2, 2003RXNo6,224,905*PEDDec 10, 2017Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,224,905

PCT Information
PCT FiledJune 10, 1997PCT Application Number:PCT/EP97/03065
PCT Publication Date:December 24, 1997PCT Publication Number: WO97/48383

International Patent Family for Patent: 6,224,905

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland330530► subscribe
New Zealand332832► subscribe
Norway985876► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.